1. Peripheral Blood WT1 Expression Predicts Relapse in AML Patients Undergoing Allogeneic Stem Cell Transplantation
   Michele Malagola et al, 2014, BioMed Research International CrossRef
2. Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation
   A Israyelyan et al, 2015, Bone Marrow Transplantation CrossRef
3. Treatment of acute mixed-cell leukemia with autologous hematopoietic SCT followed by allogeneic hematopoietic stem cell micro-transplantation
   Y-S Chen et al, 2014, Bone Marrow Transplantation CrossRef
4. Minimal residual disease in acute myeloid leukaemia
   Christopher S. Hourigan et al, 2013, Nature Reviews Clinical Oncology CrossRef
5. Identification and validation of STAT4 as a prognostic biomarker in acute myeloid leukemia
   Chenyu Li et al, 2024, Bioscience Reports CrossRef
6. Effect of the microtransplantation of allogeneic hematopoietic stem cells as maintenance therapy for elderly patients with acute leukemia
   XIANGJING KONG et al, 2015, Oncology Letters CrossRef
7. WT1 Expression in Circulating RNA as a Minimal Residual Disease Marker for AML Patients After Stem-Cell Transplantation
   Ling Zhong et al, 2015, Molecular Diagnosis & Therapy CrossRef
8. Dynamic changes in the level of WT1 as an MRD marker to predict the therapeutic outcome of patients with AML with and without allogeneic stem cell transplantation
   Huasheng Liu et al, 2019, Molecular Medicine Reports CrossRef
9. WT1 and TP53 as valuable diagnostic biomarkers for relapse after hematopoietic stem cell transplantation in acute myeloid leukemia
   Ali Asghari-Ghomi et al, 2024, Molecular Biology Reports CrossRef